Older patients with MG face higher death rates from other illnesses
Older adults with myasthenia gravis had higher overall death rates than peers without the condition, mainly due to other chronic illnesses.
News
-
-
Phase 3 trial launches to study IMVT-1402 in MG
A new Phase 3 clinical trial is underway to evaluate the efficacy and safety of IMVT-1402, a FcRn inhibitor, in patients with MG.
-
Most women with MG can have safe vaginal births
Most women with myasthenia gravis (MG) can have safe vaginal deliveries, according to a recent study published in the journal Neurology.
-
Researchers identify 2 distinct types of anti-AChR-positive myasthenia gravis
Two biologically distinct forms of anti-AChR-positive myasthenia gravis (MG) appear to differ by sex, age and immune response.
-
Patients with MG and vision loss may need screening for autoimmune retinopathy
Patients with myasthenia gravis who have vision problems should be screened for possible autoimmune retinopathy.
-
Mesenchymal stem cells show promise in easing MG muscle weakness
Mesenchymal stem cells can calm immune system attacks and slow the muscle wasting seen in MG, potentially improving strength and endurance.
-
Researchers uncover platelets’ role in driving myasthenia gravis activity
Platelets are more than blood-clotting cells; they actively influence the immune system in untreated myasthenia gravis, worsening symptoms.
-
Genetic testing may hold answers for those with seronegative MG
Genetic testing may show that some patients diagnosed with seronegative MG actually have congenital myasthenic syndrome (CMS).
-
White blood cells may contribute to MG exacerbation by secreting BAFF
The secretion of a protein known as BAFF by white blood cells contributes to the exacerbation of myasthenia gravis.
-
CNP-106 receives Orphan Drug Designation for MG
CNP-106 works by downregulating overactive immune responses in patients with generalized MG caused by anti-AChR antibodies.
